Study of ORIC-101 in Combination With Enzalutamide
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety,
pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101
in combination with enzalutamide (Xtandi®) when administered to patients with metastatic
prostate cancer progressing on enzalutamide.